ARTICLE
Received 29 Sep 2014 | Accepted 5 Jan 2015 | Published 24 Feb 2015
Jeremy Bonzi1,2, Olivier Bornet2,3, Stephane Betzi2,4, Brian T. Kasper5, Lara K. Mahal5, Stephane J. Mancini2,6, Claudine Schiff2,6, Corinne Sebban-Kreuzer1,2, Francoise Guerlesquin1,2 & Latifa Elantak1,2
Galectins are glycan-binding proteins involved in various biological processes including cell/cell interactions. During B-cell development, bone marrow stromal cells secreting galectin-1 (GAL1) constitute a specic niche for pre-BII cells. Besides binding glycans, GAL1 is also a pre-B cell receptor (pre-BCR) ligand that induces receptor clustering, the rst checkpoint of B-cell differentiation. The GAL1/pre-BCR interaction is the rst example of a GAL1/unglycosylated protein interaction in the extracellular compartment. Here we show that GAL1/pre-BCR interaction modies GAL1/glycan afnity and particularly inhibits binding to LacNAc containing epitopes. GAL1/pre-BCR interaction induces local conformational changes in the GAL1 carbohydrate-binding site generating a reduction in GAL1/glycan afnity. This ne tuning of GAL1/glycan interactions may be a strategic mechanism for allowing pre-BCR clustering and pre-BII cells departure from their niche. Altogether, our data suggest a novel mechanism for a cell to modify the equilibrium of the GAL1/glycan lattice involving GAL1/unglycosylated protein interactions.
1 Laboratoire dIngnierie des Systmes Macromolculaires, CNRS UMR7255, 13402 Marseille, France. 2 Aix-Marseille Universit, UM105, 13284 Marseille cedex 07, France. 3 Institut de Microbiologie de la Mditerrane, CNRS FR3479, 13402 Marseille, France. 4 Centre de Recherche en Cancrologie de Marseille, Institut Paoli-Calmettes, CNRS UMR 7258, INSERM U1068, 13273 Marseille, France. 5 Department of Chemistry, Biomedical Chemistry Institute, New York University, 100 Washington Square East, Room 1001, New York, New York 10003, USA. 6 Centre dImmunologie de Marseille-Luminy, Facult des Sciences de Luminy, INSERM U1104, CNRS UMR7280, 13288 Marseille, France. Correspondence and requests for materials should be addressed to L.E. (email: mailto:[email protected]
Web End [email protected] ).
NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
DOI: 10.1038/ncomms7194
Pre-B cell receptor binding to galectin-1 modies galectin-1/carbohydrate afnity to modulate specic galectin-1/glycan lattice interactions
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194
Lectins on cell surfaces mediate cellcell contacts by interacting with specic carbohydrates on apposing cells. The lectins that bind to cell surface glycoproteins are often
multivalent. As well, glycoproteins often bear multiple copies of the saccharide ligand that are recognized by lectins1,2. The multivalent nature of both lectins and their saccharide ligands allows the formation of a lectincarbohydrate lattice, which acts as a signalling complex at the cell surface. These lectin glycoprotein lattices are characterized by multiple low-afnity interactions, resulting in high overall avidity35. However, these organized interacting structures are not xed and can be modied according to the cells needs. Only two modes have been described to dynamically modulate the strength of the lattice interactions: (i) altering protein glycosylation or (ii) altering lectin expression6. One family of multivalent lectins that can organize cell surface lattices is the galectins7. Galectins preferentially bind b-galactoside-containing glycans comprised of repeating units at the termini of complex N-glycans or as repeating units in a poly-N-acetyllactosamine chain on N-glycan or O-glycan79. The galectins share a common carbohydrate recognition domain (CRD) responsible for b-galactoside binding10 and have been shown to be involved in cell interactions, proliferation, migration, apoptosis and mRNA splicing3,1113. Galectins are also associated with different pathologies and most importantly with cancer14, thus providing targets for novel anticancer therapies. Among galectins, galectin-1 (GAL1) is differentially expressed by various normal and pathological tissues and appears to be functionally polyvalent, with a wide range of biological activities15. The overall folding of GAL1 involves a b sandwich consisting of two anti-parallel b-sheets forming a concave and a convex side. This jellyroll topology of the CRD constitutes the typical folding patterns of galectins. The concave side forms a groove which accommodates the carbohydrate: the carbohydrate-binding site (CBS). The CBS can be schematically described as having ve subsites (AE) with subsites C and D dening the conserved core b-galactoside-binding site16. Human GAL1 exists as a dimer in solution17 and the presence of more than one CRD in a GAL1 homodimer makes it well suited for mediating cell adhesion, eliciting signalling and forming lattices7,14.
We previously evidenced a crucial role of GAL1 in B-cell development through the formation of a GAL1-dependent lattice between pre-BII and stromal cells1821. B cells are generated from haematopoietic stem cells and develop in the bone marrow before they migrate into the blood to reach peripheral lymphoid organs. While the diversity of B-cell repertoire is generated by the rearrangement of the Ig gene loci, checkpoints are needed during the differentiation process to ensure that the surface-expressed antigen-specic B-cell receptor (BCR) is functional yet not autoreactive22. Expression of the pre-B cell receptor (pre-BCR) represents a crucial checkpoint during B-cell development as this receptor controls pre-BII cell development and the selection of the Igm repertoire23. We have found that pre-BII cells are associated to medullar stromal cells secreting GAL1 that constitute a specic pre-BII cell niche in the bone marrow21. At the contact zone between pre-BII and stromal cells, GAL1, pre-BCRs and glycosylated integrins relocalize18. This relocalization is allowed by the dual interaction network of GAL1 with the pre-BCRs (proteinprotein interactions) and with glycosylated counter receptors (proteinoligosaccharide interactions) at the cell surfaces1820. To date, this GAL1/pre-BCR interaction is the rst example of a GAL1/unglycosylated protein interaction in the extracellular compartment. This immune developmental synapse is accompanied by the initiation of intracellular tyrosine kinase activity and signal transduction from the pre-BCR18,19.
The pre-BCR is constituted of two heavy chains, two surrogate light chains (SLCs) and the CD79a/b signalling molecules. GAL1
has been shown to interact directly to the SLC (KD of 0.5 mM) (ref. 18). Each SLC is composed of the l5 and VpreB proteins. The N terminus of l5 and the C terminus of VpreB contain unique regions (l5-UR and VpreB-UR, respectively) crucial for pre-BCR cell surface expression24,25 and pre-BCR activation18,24. We recently found that GAL1 interacts with a l5-UR motif, l5-UR22-45, of the pre-BCR that adopts a stable helical conformation that docks onto a GAL1 hydrophobic surface adjacent to the CBS26. We hypothesized that this close proximity of the two interacting surfaces might then inuence the carbohydrate-binding event when the l5-UR22-45 peptide is bound to GAL1. Interestingly, on l5-UR binding, the lactose-binding activity of GAL1 undergoes a fourfold decrease, while no binding afnity changes have been observed for GAL1/ l5-UR22-45 interaction in the presence versus in the absence of lactose26. These modulations suggest that the pre-BCR could modulate GAL1 afnity for specic glycoproteins26 by a mechanism that would be a strategic step at the synapse level to modify the crosslinked lattices. Our hypothesis is supported by a recent study on a non-natural peptide, Anginex, suggesting that this peptide is able to enhance GAL1 carbohydrate-binding afnity for glycoproteins27. This peptide has been developed to inhibit tumour growth through specic inhibition of angiogenesis28,29. There are many text book cases where a stronger or weaker binding activity of one protein is induced by another protein or smaller molecule, but the molecular and structural basis of such effects have not been described yet for the carbohydrate-binding activity of galectins.
Here we demonstrated that on binding to the l5-UR of the pre-BCR, GAL1 undergoes selective afnity changes in its carbohydrate-binding activity. By exploring the glycome of pre-BII and stromal cells, we identied the presence of certain glycans for which GAL1 presents afnity changes when bound to the pre-BCR on the cell surfaces. These carbohydrate-binding activity changes have been explained at atomic resolution level by the modication of several intermolecular contacts between GAL1 and the carbohydrate. Such carbohydrate-binding modulation of GAL1 when bound to the pre-BCR allowed us to propose a model for the sequential interactions involved in pre-BCR relocalization and pre-BII cell departure from the niche. Collectively, our ndings provide the structural basis of a new mechanism by which a galectin-dependent lattice can be dynamically modulated independently of alteration of protein glycosylation or lectin expression. Moreover, these results provide a new road map for developing inhibitors targeting galectin-dependent lattices in pathological situations such as cancers.
ResultsGAL1 carbohydrate-binding specicity when bound to k5-UR.
To investigate whether the changes induced by l5-UR interaction to GAL1 modify its carbohydrate-binding specicity, we performed glycan array screenings of GAL1 free and bound to l5-UR. Fluorescently labelled GAL1 at 5 mg ml 1 was used to probe a glycan array offered by the Consortium of Functional
Glycomics (CFG; Fig. 1). GAL1 exhibits strong binding on glycan arrays toward LacNAc terminated complex type bi- and triantennary carbohydrates (Supplementary Fig. 1) as it was previously observed30. The glycomic patterns for both GAL1 free and bound to l5-UR, are similar (Fig. 1a,b) suggesting no drastic changes such as an on/off switch in binding specicity of GAL1 when bound to l5-UR. However, the uorescence intensities for several of these glycans are not strictly identical in the presence of l5-UR. These changes were also observed when the same experiments were performed with GAL1 at 25 mg ml 1 (Supplementary Fig. 2). Therefore, besides this global analysis,
2 NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194 ARTICLE
Galectin-1 Galectin-1/5-UR
581 582 584 586 588
581 584 586 588
10,000 19
363 387
485
9,000
8,000
7,000
6,000
565
Relative fluorescence units (RFU)
Relative fluorescence units (RFU)
560 19 54
325
369
54
5,000
4,000
3,000
2,000
1,000
0
10,000
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
363
387
485
325
1 51
101
151
201
251
301
351
401
451
501
551
601
1 51
101
151
201
251
301
351
401
451
501
551
601
40
30
27
i
4
31
3
3O
6O
261
ii
3 4 4
3
3O
= (normRFUgal-1 bound normRFUgal-1 free )*100
3 sialyl-LacNAc
4 4
3
259
382
35
20
10
0
10
20
30
3O
6O
471 544
565
54
132
353
325 369
3 3
584
iii
4 4 4
4
4
6
115
4
4
4
3
3
4 2
3
6
6
2
3 3
19
531
3
4 4
4
3
3
485
4
6
4
3
163
164
386
3 3
4 2
6
4
6
3
3
4 4
4 4
4
582
Lacto-N-neotetraose
N-Acetylgalactosamine Fucose Sialic acid Glucose Mannose
549
4 4 4
4
4
2
2
6
161
3
3
3
3
3 3
4 2
4 4 4
3
3
v
4 4 4 2
3 3
162
iv
6
555
4 4 4
4 4
3 3
2
Galactose N-Acetylglucosamine
Figure 1 | Carbohydrate-binding specicity of GAL1 free and bound to k5-UR. Fluorescently labelled GAL1 was analysed for binding to the mammalian glycan array (V5.1) of the CFG when free (a) or bound (b) to l5-UR. Results shown for each plot are averages of two biological replicate measurements of uorescence intensity at a lectin concentration of 5 mg ml 1. Error bars indicate the s.e.m. for two experiments. The raw data and the entire list of glycans with the respective spacers can be found on the CFG website (http://functionalglycomics.org/
Web End =http://functionalglycomics.org /). Glycans presenting the highest relative uorescence intensity are indicated with their number ID (The structure of these glycans is depicted in Supplementary Fig. 1). (c) Relative uorescence intensity comparison for each glycan between free and l5-UR bound GAL1. The uorescence intensities measured in a and b have been normalized and the differential plot between free and bound GAL1 has been generated. Positive and negative bars indicate a higher and a weaker binding of GAL1, respectively, for the glycan in the presence of l5-UR. Glycan structures and number ID are depicted for several epitopes with signicant relative uorescence difference and sharing similar structural motifs (clusters of bars presenting signicant differences are numbered from (i) to (v)).
we performed a detailed cross-analysis of the two data sets by normalizing the relative uorescence of each glycan on each array and compared if this normalized relative uorescence has increased or decreased when l5-UR is bound to GAL1 (Fig. 1c). The difference of normalized uorescence intensities pinpoints changes in GAL1 binding for several glycans, when GAL1 is bound to l5-UR (Fig. 1c). Increased binding of GAL1 is observed for structurally related groups of glycans including:(i) lactose and N-acetyllactosamine (LacNAc) mono or disulfated;
(ii) a3 sialylLacNAc and a3 sialyllactotetraose glycans. In this study, we have considered and selected as signicant only the carbohydrate-binding changes of the l5-UR bound GAL1 when changes in structurally related groups of glycans are observed at 5 mg ml 1 (Fig. 1) and 25 mg ml 1 (Supplementary Fig. 2). We also observed signicant decreased binding for several high binding glycans (Supplementary Fig. 1) when GAL1 is bound to l5-UR. Binding to three groups of structurally related glycans were then identied as decreased: (iii) branched LacNAc
NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194
pentasaccharide; (iv) tetra- and hexasaccharides, mostly consisting of LacNac repeats fucosylated or not; (v) LacNAc complex type, biantennary carbohydrates fucosylated and unfucosylated. These data suggest that l5-UR binding to GAL1 differentially modulates GAL1-binding activity for structurally related carbohydrates.
Quantication of GAL1 afnity changes for selected glycans. To validate and quantify the changes observed on the glycan array data (Fig. 1c), we used isothermal titration calorimetry (ITC) measurements of GAL1 binding to selected glycans (Supplementary Fig. 3 and Supplementary Table 1). We tested two glycans, the lacto-N-neotetraose (LNnT) belonging to group (iv) (Fig. 1c) and the a3 sialyl-N-Acetyllactosamine (a3 SiaLacNAc) belonging to group (ii) (Fig. 1c), for which a relative decrease and increase in GAL1 binding, respectively, are observed in the presence of the l5-UR domain (binding of these two glycans to GAL1 has been demonstrated previously31,32). In our experimental conditions, the dissociation constant (KD) of
GAL1/LNnT interaction obtained is 516 mM, whereas when GAL1 is bound to the l5-UR domain, the KD increases to 13010 mM, that is, a 2.5-fold decrease in binding afnity of LNnT for GAL1 in the presence of l5-UR (Supplementary Table 1). The KD measured for GAL1/a3 SiaLacNAc complex formation is 24020 mM. In the presence of l5-UR, the KD reaches 252 mM, that is, a 10-fold increase in binding activity. As a control, we tested for binding the LacNAc for which no GAL1 binding change is observed in the presence of l5-UR according to the glycan array. The KD evaluated from the ITC measurements do not show signicant afnity changes when GAL1 is bound to l5-UR (Supplementary Table 1). Therefore, these results are in agreement with the binding changes of GAL1 for these glycans observed qualitatively on the glycan array screening (Fig. 1c).
Altogether, the glycan array and ITC experiments demonstrate that l5-UR binding to GAL1 is able to modify the GAL1 carbohydrate afnity for selected glycans. When placed in the context of the pre-B synapse, this phenomenon argues for pre-BCR-driven modication of the GAL1/glycans binding equilibria within the lattice. To investigate the presence on the cells forming the pre-B synapse of one or several groups of the identied glycans, it was then crucial to explore the glycome of pre-BII cells and stromal cells secreting GAL1 for which no glycomic data were available.
Glycomic exploration of pre-BII and stromal cells GAL1 . To establish the biological relevance of the differences observed
on glycan array screenings, we performed glycomic analysis of Nalm6 pre-BII and OP9 stromal cell lines using lectin microarray experiments. These cell lines have been chosen since they have been used in many functional assays1820,26 to study the role of GAL1 and GAL1/pre-BCR interaction for pre-BCR relocalization and signalling. We have shown previously that, similarly to normal pre-BII cells, the Nalm6 pre-B cell line expresses pre-BCRs and integrins required for the formation of the pre-B cell synapse and the induction of an efcient pre-BCR signal1820,26. In addition, OP9 stromal cells were shown to strongly support normal pre-BII cell differentiation, due to the expression of GAL1 and integrin ligands required for the formation of the pre-B cell synapse20. Therefore, even though immortalized cells often show alterations of cell surface receptors, pre-BCR relocalization and signalling using Nalm6 and OP9 cells reect what is observed in primary cells. In lectin microarrays, carbohydrate-binding proteins (lectins; for a list of lectin abbreviations, see Supplementary Table 2) are immobilized onto a solid support at a high spatial density33,34. Interrogation of the arrays with uorescently labelled sample enables elucidation of the glycome based on the distinct carbohydrate-binding specicities of the lectins. This method has been used to analyse the glycomic ngerprint of viruses35, bacteria36, mammalian cells37 and tissues38 in a high-throughput manner. Proling of Nalm6 pre-BII and OP9 stromal cell samples using single-colour analysis showed that both cell types displayed GAL1 ligands such as poly/multiantennary LacNAc as conrmed by GAL1, ECA, LEA, PHA-L and WGA binding on the arrays (Fig. 2; for a list of lectin abbreviations, see Supplementary Table 2). More specic epitopes such as a3 sialylated/sulfated glycans as well as bi-and multiantennary N-glycans are found on both cell types thus indicating the presence of group (i) to (v) glycan epitopes on both cells (Fig. 3). Given that the stromal cells have high secretion of GAL1, it was important to address if this lectin could occlude binding of the galectin ligands by the lectins on the microarray. To address this concern, cells were treated with lactose. Cells treated with lactose showed no signicant differences in glycan signature compared with untreated OP9 (Supplementary Fig. 4), indicating that sample preparation before hybridization on the array (cell sonication and extensive dialysis)37 remove most of the GAL1 bound to the cells.
To identify the higher expression of one or several glycans on one of the cell type with respect to the other, biological triplicates of Nalm6 pre-BII and OP9 stromal cell samples were analysed using dual-colour lectin microarray technology, which provides a more sensitive and semi-quantitative comparison37. This analysis revealed no signicant differences in poly/multiantennary LacNAc levels, although specic glycomic proles for each cell
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
0 PHA-L ECA Galectin-1 LEA WGA PHA-L ECA Galectin-1 LEA WGA
Figure 2 | Nalm6 pre-BII and OP9 stromal cells contain GAL1 ligands. Single-colour analysis of poly/multiantennary LacNAc on OP9 and Nalm6 by lectin microarray is shown. Graph displays the median normalized uorescence for selected LacNAc binding lectins binding to OP9 and Nalm6.
All lectins are above the 1,000 uorescence unit threshold for binding (red line) and show signal-to-noise ratios 45, dening them as positive. Error bars represent s.d. for n 3 spots on a single microrarray. These data are consistent with previous results on a biological replicate. Binding of lectin
is as follows: GAL1, Galectin-1 ligands; LEA, polyLacNAc chains; PHA-L: multiantennary LacNAc, WGA and ECA: terminal LacNAc residues.
Fluorescence (A.U.)
35,000
30,000
25,000
20,000
15,000
10,000
5,000
40,000
Nalm-6 OP9
4 NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194 ARTICLE
OP9 (median normalized log 2fluorescence over reference)
2.5
2
1.5
1
0.5
0
0.5
TJA-I
Ricin B chain
WGA vector
AOL
AAL EEA
MOA
2-25 LE (LeB Ab)
Galectin-1 his-taggedLPA
UDA LEA
MAL-II
PTA
Calsepa Jacalin rGRFT SBA
LcH
AAA
SNA APP
PMAAMA BPA UEA-II
Lotus
Con A
RPA
LFA
EEL
MNA-M
rSVN
PHA-E
PSA PHA-L UEA-I
MNA-G
WGA EY
HHL
WFA
GNA
HAA
TJA-II
PSL
IRA
LPA ACA
PTA MAL-I
MPA
Cholera toxin
Blackbean
GNL
SJA
MAA
GS-I
1
1.5
2
2.5
2.5 2 1.5
Nalm6 (median normalized log2 fluorescence over reference)
= P > 0.05 = P 0.05 = P 0.01
= Mannose binders= Bi-Antennary N-Glycans = Core 1/3 O-Glycans= Galectin-1= Core 1 sulfation /
3 sialylation O-glycans
1 0.5 0 0.5 1 1.5 2 2.5
Figure 3 | Glycosylation differences for Nalm6 pre-BII versus OP9 stromal cells as identied using dual-colour lectin microarrays experiments. Biplot of lectin array data averaged over three biological replicates for Nalm6 versus OP9 cells. Colour represents lectin binding preference and shape represents levels of P based on Students t-test.
type were observed (Fig. 3). OP9 Stromal cells were signicantly enriched in high mannose (Fig. 3, Calsepa, GNL, HHL, MNA-M, rGRFT rSVN, UDA, Po0.05 for Calsepa and MNA-M, Students t-test). Core 1/3 O-glycans were also enriched, although individually none of the lectins were signicantly so (Jacalin, MNA-G, MPA). Pre-BII cells showed signicant enrichment in biantennary N-glycans (AMA ConA, UEA-II, Po0.05 for all three lectins) and in binding to a3 sialylated/sulfated core-1 O-glycans (ACA, Po0.01, for annotation see CFG data set,39).
These experiments suggest that biantennary N-glycans found in group (v) (Fig. 1c) and a3 sialylated/sulfated core-1 O-glycans, whose groups (i) and (ii) glycan epitopes can be part of (Fig. 1c), are more exposed on Pre-BII cells compared with stromal cell lines. Our glycan and lectin array experiments indicate that, when bound to the pre-BCR, GAL1 would modify its glycan-binding equilibria within the synapse by changing its afnity for glycans found on both cell types inducing a ne tuning of the lattice interactions at the synapse level.
To understand at the atomic level how these variations in GAL1 carbohydrate binding can occur, a more detailed structural analysis of GAL1 carbohydrate binding in the presence of l5-UR is needed.
The GAL1/LNnT and GAL1-k5-UR22-45/LNnT interactions. To elucidate the structural basis of the consequences induced by l5-UR binding on carbohydrate activity of GAL1, we have further studied GAL1 interaction with the Lacto-N-neotetraose (group (iv), Fig. 1c), motif which can be part of a more complex glycan structure at the cell surface, using ITC and NMR spectroscopy. For this structural study, we used the l5-UR22-45 peptide, a 24 amino-acid peptide of the l5-UR domain shown to be sufcient for interaction with GAL1 (ref. 26). We rst checked using ITC that the presence of the l5-UR22-45 peptide induces the same GAL1 afnity changes for LNnT as the full-length l5-UR domain does. Indeed, a threefold decrease in binding afnity is
observed when GAL1 is complexed to the l5-UR22-45 peptide (Supplementary Table 1 and Supplementary Fig. 5) as similarly shown above when GAL1 is complexed to the full-length l5-UR domain (Supplementary Table 1 and Supplementary Fig. 3a,b).
We then mapped the interaction sites of LNnT on GAL1 using NMR spectroscopy (Figs 4 and 5, respectively). We rst monitored the NMR resonances of the 15N-labelled GAL1 in the absence and in the presence of LNnT (Fig. 4a). Addition of LNnT elicited large chemical shift perturbations (CSPs) in a subset of 15N-labelled GAL1 amide resonances. A single cross-peak per GAL1 amide was observed during the titration, indicating a fast exchange between the free and the bound states on the NMR timescale, in accordance with the KD observed using
ITC (110 mM). As expected, most of the perturbations co-localize mainly to the CBS (Fig. 4b) including residues His52, Trp68, Arg73 and Val59 which are known to provide stacking Van Der Waals interactions or hydrogen bonds with carbohydrates. The residues undergoing signicant chemical shift variations belong to the subsite C (Asn50, His52, Trp68), D (Gly53, Asp54, val59, Glu71, Arg73) and E (Gly69, Thr70) of the CBS16. It is to be noticed that the subsite D is directly adjacent to the l5-UR22-45-interacting surface. Few residues from the backside of the protein, including Cys16, Phe91 and Gly103, were also signicantly perturbed. It has been previously observed in the case of lactose binding to 15N-labelled GAL1 that similar CSPs are induced, that is, at and away from the GAL1 CBS, suggesting that conformational dynamic perturbations could occur in the protein on carbohydrate binding40.
We next performed the same NMR experiments with a preincubation of GAL1 with l5-UR22-45 peptide to allow the proteinpeptide complex formation. Titrations of LNnT to the
15N-GAL1/l5-UR22-45 complex showed weaker GAL1 resonance perturbations indicative of a weaker binding of the carbohydrate when GAL1 is complexed to the peptide (Fig. 5 and Supplementary Fig. 6). This result is in agreement with the observed KD and glycan array experiments. Among the perturbed
NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications 5
& 2015 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194
GAL1 + LNnT
GAL1-5UR2245
+ LNnT
110
110
115
15N(p.p.m.)
115
120
125 W68
R73
15N(p.p.m.)
120 R73
D64
D64
W68
125
130
V59
V59
130
8.5 1H(p.p.m.)
90 rotation
(y axis)
10.0 9.5 9.0 8.5 1H(p.p.m.)
10.5 10.0 9.5 9.0
N56
8.0 7.5 7.0 6.5 6.0
10.5
N56
N50 A55 G53
T57
8.0 7.5 7.0 6.5 6.0
N50 A55 G53
T57
5-UR
H52
H52
D
G103
C R73 G103
C16
D
R73
E71 W68
C
90 rotation (y axis)
E71
C16
W68
E
E
F91
F91
Figure 4 | Mapping LNnT binding on GAL1. (a) Overlay of 2D 1H,15N HSQC spectra of GAL1 in the free form (blue) and with a fourfold molar excess of LNnT (red). Expanded regions show resonances representative of those that showed large CSPs on binding to LNnT. (b) CSPs induced by LNnT binding mapped onto the GAL1 surface (PDB 1GZW). Monomer surface structure is represented. CSPs have been coloured from blue to iodine (CSPo0.05: blue, o0.1 marine, o0.125: greencyan, o0.15: green, o0.175: lemon, o0.2: yellow orange, o0.225: orange, o0.25: red, o0.275: iodine). White is used for unassigned residue resonances.
Subsites CE of the GAL1 CBS are delineated with pink and yellow dotted lines. The l5-UR22-45-interacting site is indicated using dotted grey lines.
Figure 5 | Mapping LNnT binding on GAL1 in the presence of the k5-UR22-45 peptide. (a) Overlay of 2D 1H,15N HSQC spectra of GAL1 bound to l5-UR22-45 (blue) and with a fourfold molar excess of LNnT (orange). Expanded regions show resonances representative of those that showed large CSPs on binding to LNnT. (b) CSPs induced by LNnT binding mapped onto the GAL1 surface (PDB 1GZW). Monomer surface structure is represented. CSPs have been coloured from blue to iodine (CSPo0.05: blue, o0.1 marine, o0.125: greencyan, o0.15: green, o0.175: lemon, o0.2: yelloworange, o0.225: orange, o0.25: red, o0.275: iodine). White is used for unassigned residue resonances. Subsites CE of the GAL1 CBS are delineated with pink and yellow dotted lines. The l5-UR22-45 peptide is represented as grey ribbon and its interacting surface on GAL1 is delineated with dotted lines.
resonances, Arg73 showed the strongest decrease in chemical shift variations when GAL1 is bound to the peptide (Fig. 5b and Supplementary Fig. 6). Arg73 belongs to subsite D of the CBS and is really localized at the junction between the CBS and the l5-UR-binding site (Fig. 5b). Analysis of the structure of the
GAL1/l5-UR22-45 complex26 shows that Arg73 is oriented toward the peptide in the GAL1 bound conformation, whereas it faces the CBS and therefore the carbohydrate in the peptide free conformation of GAL1 (Fig. 6). Altogether our data suggest that binding of the l5-UR22-45 peptide to GAL1 induces structural modications in the subsite D of the CBS among which Arg73 side-chain reorientation. These changes lead to carbohydrate binding destabilization resulting in the observed reduced afnity of GAL1 for LNnT.
Epitope mapping of LNnT bound to GAL1 and GAL1/k5-UR22-45. Since l5-UR binding to GAL1 induces structural modications resulting in a binding afnity decrease of GAL1 for LNnT, we next investigated at atomic resolution the mode and orientation of LNnT binding to GAL1 and GAL1/l5-UR using saturation transfer difference (STD) NMR experiments41 (Fig. 7). STDNMR is a ligand-based NMR experiment enabling the mapping
of the ligands binding epitope. The STD NMR protocol is based on the intermolecular saturation transfer from the protein to the binding part of the ligand. The part of the ligand having the strongest contact to the protein shows the most intense NMR signals. As a rst step to this study, we assigned 13C (96%) and 1H (100%) NMR resonances of LNnT using homo- and heteronuclear two-dimensional (2D) NMR experiments (Fig. 7a). STD-NMR experiments were recorded on a sample containing a 100-fold molar excess of LNnT relative to GAL1 before and after addition of threefold molar excess of l5-UR22-45. Some characteristic features of the LNnT-binding epitope are revealed by the inspection of 1D STD-NMR spectra. In the presence of GAL1 (Supplementary Fig. 7), a clear binding epitope exists since not all of the 1H NMR signals of the tetrasaccharide (Supplementary Fig. 7) were displayed in the STD spectrum. The N-acetyl group attached to the N-acetylglucosamine (HNGlcNAc), and the H1 and H4 from the internal galactose(C) moiety clearly receive strong saturation transfer, whereas the H1 and H2 from the glucose (D) moiety receive much less. Therefore, these spectra suggest that the GlcNAc and the internal galactose residues are in close proximity with GAL1. When the
6 NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194 ARTICLE
5-UR2245
R73
R73
Lactose
Figure 6 | Structural changes induced by k5-UR22-45 binding to GAL1. The structures of GAL1/l5-UR22-45 (in light blue and grey, respectively)
and GAL1/lactose17 (in beige and green, respectively) complexes are superimposed. Side chains of Arg73 residue from each structure are represented and labelled.
l5-UR peptide is bound to GAL1 (Supplementary Fig. 7), the STD spectrum is globally similar to the one recorded in the absence of l5-UR22-45 (Supplementary Fig. 7) but signicant differences in peak intensities can be observed especially in the 4.0 to 3.4 p.p.m. region. At this stage, due to heavy overlapping observed in this region, no ne details of the contributing moieties could be obtained in an unambiguous manner. To obtain information on ligand signals that are heavily overlapped, 2D STD TOCSY experiments were performed to resolve the STD signal in a second dimension (Fig. 7). A simple epitope mapping on the basis of STD TOCSY spectra is easily achieved for isolated spin systems, such as the ones found for pyranose rings in oligosaccharides. Spin diffusion across glycosidic linkages can be neglected and, therefore, a qualitative comparison of the corresponding cross-peaks readily identies pyranose units in intimate contact with the GAL1 CBS. It is immediately obvious that mainly the cross-peaks of the GlcNAc (B) display the largest overall intensities (Fig. 7b), indicating that the protons of this pyranose ring are in close contact with the GAL1 protein as suggested in the 1D STD spectrum (Supplementary Fig. 7). The internal galactose (C) and the glucose (D) moieties present signicant cross peak intensities thus indicative of proximity with the protein. The terminal galactose (A) provided few and weaker STD effects indicating that it mainly remains outside of the main protein-binding site. Relative ranking of the amount of saturation that is transferred to individual spin have been done for LNnT binding to GAL1 (Fig. 7b, right panel). The major contributions for GAL1/LNnT binding involve H2, H4 and H6 from the GlcNAc (B) moiety, H1 and H4 from the internal Gal (C), and H3 and H4 from the terminal glucose (D). When GAL1 is bound to the l5-UR22-45 peptide, several cross-peaks of the STD spectrum show a signicant global decrease of STD signals (Fig. 7c). These observations are indicative of a loss of several LNnT/GAL1 contacts in the presence of the l5-UR peptide.
Integration of 2D STD signals revealed that the contacts involving H3 and H4 from the terminal glucose (D) experienced the strongest decrease in STD signal intensity (Fig. 7c, right panel). Indeed, while most of the STD signals are decreased by 35% on average, the STD signals from H3 and H4 from the terminal glucose decrease by B70%. These results indicate that the l5-UR
peptide induces a loss of contacts mainly at the level of the terminal glucose (D) thus affecting the strength of binding of the rest of the LNnT molecule.
When compiled together, the results obtained on GAL1 binding to LNnT using ITC and NMR support a structural modication of the CBS when the l5-UR peptide is bound to
GAL1. Indeed, an unfavourable entropy is observed (Supplementary Table 1) that could indicate a decrease of exibility in the CBS on l5 binding thus changing the CBS dynamic properties for LNnT binding. In that sense, we previously observed that binding of the l5-UR peptide to
GAL1 induces NMR CSPs on the backside of the protein, its interacting surface, but also in the subsites C and D of the CBS26. Accordingly, we can propose that the GlcNAc and the internal galactose of LNnT bind to the center of the CBS subsites C and D of GAL1, whereas the terminal glucose is localized in the part of the subsite D of the CBS that undergoes structural rearrangements on l5-UR binding, as illustrated by Arg73 side-chain reorientation. This structural change leads to a loss of contacts between LNnT and GAL1 and thus a decrease of GAL1/ LNnT afnity. We can therefore conclude that GAL1/l5-UR interaction inhibits GAL1/LNnT binding as suggested by glycan array experiments (Fig. 1c).
DiscussionGalectin/glycan lattices play leading roles in signal transduction in different biological processes as well as in cellcell interactions42. To the best of our knowledge, the GAL1/pre-BCR interaction is the rst example of a GAL1/protein interaction with an unglycosylated protein-binding partner (l5 UR) in the
extracellular compartment. We have demonstrated that l5-UR binding to GAL1 induces structural modications in the CBS including Arg73 side-chain reorientation (Fig. 6) probably associated to a decrease in CBS exibility. Indeed, GAL1/l5-UR complex formation leads to CSPs throughout the CBS from subsite A to E26. LNnT, a glycan that represents group (iv) as designated in Fig. 1c, binds mainly to subsites C to E of the GAL1 CBS (Fig. 4). Together with groups (iii) and (v), these structures show a weaker binding to GAL1 bound to l5-UR. Groups (iii)
and (v) present branched and/or more extended structures compared with the LNnT that would protrude from the D subsite of GAL1 towards subsite E and towards the l5-UR-binding site.
Therefore, one can expect that the CBS modications induced by the l5-UR interaction to GAL1 perturb the binding of these glycans as suggested by the glycan array data (Fig. 1c). Conversely, glycans from groups (i) and (ii) among which a3
SiaLacNAc, showing enhanced binding to GAL1 when complexed to l5-UR (Fig. 1c, Supplementary Fig. 3c,d and Supplementary
Table 1), contain sulfate groups or a3 sialylation on the terminal galactose. These sugar modications should be localized at the subsites AB for galactose modications and at subsite D (top of subsite D) for Lac or GlcNAc modications as suggested previously30. This localization is no within the structurally negative perturbations induced by l5-UR binding evidenced at the subsite D (Figs 57), explaining the differential effects of l5-UR binding on recognition of groups (i) and (ii) versus groups(iii) to (v) as seen on the glycan arrays (Fig. 1c).
Studies on the non-natural peptide anginex have shown that it
greatly enhances the afnity of GAL1 for certain ligands, including biologically relevant glycoproteins27. Moreover, a topomimetic of anginex, the calixarene 0118, has been shown to be an allosteric inhibitor of GAL1 lactose binding, interacting with a surface of GAL1 located on the back face of the protein43. Therefore, anginex have opposite effects on GAL1 carbohydrate-binding activity depending on the carbohydrate substrate tested.
NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194
2D TOCSY LNnT
3.2
D2
D6a A2
A3 C3
3.4
D1
Lacto-N-neotetraose (LNnT)
Relative STD signal
C2
D5 D3/4
D6b
A B
C D
HO HO
3.6
B4
C4
3.8
4 4 4
p.p.m.
A4
A1 C4
C1
4
3 3
3 3
5 2 5 2 5 2
5 2
OH OH OH OH
OH OH OH
OH
NH
40% 70%
LNnT+ GAL1
6 6 6
6
HO HO
O O O O
O
O
1 1 1
1
HO
4.0
4.2
B5
4.4
4.6
B1
4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.1 p.p.m.
2D STD TOCSY LNnT+ GAL1
3.2
A3
100%
3.4
D3/4
C3
C4
3.6
B4
A B C D
HO
HO HO
HO
p.p.m.
3.8
B62
OH OH OH
OH OH
H
H
H H
H
OH
4.0
O O O
O
H
H
H H H
H
H
1
H
H
O
H
H
H
H H
O O
H
H
4.2
OH
C2
B61
H NH
OH
H H H
H
HO
C1
D2
D1
O
H H H
4.4
A1
A4
B4
B2 B5
B1
4.6
4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.1 p.p.m.
2D STD TOCSY LNnT+ GAL1+5UR2245
Relative STD signal
40% 70% 100%
3.2
3.4
LNnT+ GAL1+5UR2245
3.6
A B C D
HO
HO HO
HO
3.8
p.p.m.
OH OH OH
OH OH
H
H
OH
H H
H
H H H
H
4.0
H H H
H
H
H
H
O O
O
O
H
H
H
O O O
H
H
OH
OH
H H H
H
HO
4.2
H NH
O
H H H
4.4
4.6
4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.1 p.p.m.
Figure 7 | Mapping the LNnT-binding epitope using 2D STD-NMR spectroscopy. (a) 2D TOCSY spectrum of LNnT (from 3.1 to 4.6 p.p.m.) is shown on the left panel with several cross-peaks assignment. Proton cross-peaks are labelled according to the nomenclature shown on the right panel.(b) 2D STD TOCSY spectrum of LNnT in the presence of GAL1 is represented on the left panel. The cross-peaks showing the highest intensity are circled and assignment is indicated. The circles are colour coded according to the monosaccharide they belong to: terminal galactose: magenta, N-acetylglucosamine: red, internal galactose: green, terminal glucose: blue. On the right panel, the signicant relative STD signals observed are reported on the LNnT and are colour coded according to the colour scale shown above. The 100% STD signal corresponds to the resonance showing the highest intensity contribution in each experiment; all other STD signals are calculated accordingly. (c) 2D STD TOCSY of LNnT GAL1 l5-UR22-45 is shown on
the left panel. On the right panel, the relative STD signals observed are reported on the LNnT as in b.
Here we observed a threefold decrease for LNnT and a 10-fold increase for a3 SiaLacNAc GAL1-binding afnity in the presence of l5-UR. We cannot exclude that l5-UR could induce a higher effect on GAL1 binding to other more complex glycans and entire glycoproteins. It has been proposed that anginex may mimic a normal function, meaning that there is a natural counterpart in vivo27. Therefore, unglycosylated protein binding to GAL1 could represent a key regulator of GAL1/glycan interactions in the extracellular compartment.
Relative concentration of GAL1 and of its various ligands can change the afnities within the crosslinked GAL1-dependent lattices. In that sense, dynamic modulation by the cell of protein
glycosylation or lectin expression at the cell surface has been proposed as ways for the cell to modify its lectin/glycan equilibria. Quantication of the afnity change with the LNnT led to a threefold decrease in GAL1/LNnT-binding afnity in the presence of l5-UR. A 10-fold increase in GAL1 binding has been observed for a3 SiaLacNAc. A three- or a 10-fold change on these individual interactions will result in a more dramatic effect within the context of galectin/glycan lattices consisting of multivalent interactions generating high avidity. Indeed, calixarene 0118 has been shown to be a potent angiogenesis inhibitor in vitro, as determined by endothelial cell proliferation, migration and chick embryo chorioallantoic membrane assays44
8 NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194 ARTICLE
GAL1
GAL1
Stromal cell
Stromal cell
Stromal cell
Stromal cell
Pre-BII cell
Pre-BII cell
Pre-BII cell
Cell signalling
LacNAc epitopes
GAL1
Pre-BCR
CD79a/b
Fibronectin
Pre-BCR relocalization
Integrins
Figure 8 | Model of pre-B cell synapse formation. (a) GAL1 secreted by stromal cells is bound to LacNAc epitopes presented by stromal cell integrins and receptors. (b) When a pre-BII cell contacts the stromal cell, pre-BII cell integrins interact with their stromal cell ligands and GAL1 can bind Pre-BCRs and glycosylated receptors. (c) On binding to the pre-BCRs, GAL1 undergoes a decreased afnity for LacNAc epitopes thus weakening its anchoring to both cell glycans. GAL1 is then available for interaction to better ligands found on pre-BII cell relocalizing integrins. (d) The molecularlink established by GAL1 between relocalizing pre-BII cell integrins and pre-BCRs drives these latters at the contact zone between the two cells. Relocalization of the pre-BCRs leads to cell signalling necessary for pre-BII cell differenciation and proliferation.
and was also found to be highly effective at inhibiting tumour angiogenesis and tumour growth in murine tumour models (that is, MA148 human ovarian carcinoma and B16 murine melanoma)44. This molecule targets GAL1 as does Anginex at a site away from the CBS and attenuates lactose binding to the lectin by a threefold43 illustrating that a threefold difference in afnity can be relevant to an in vivo situation. This process is not an on/off switch of GAL1 carbohydrate specicity; rather, we conclude that there is a ne tuning of the afnity of these interactions depending on the cell needs. This is an original and unforeseen way for a cell to modify the equilibria of the GAL1/glycan lattice besides changes in protein glycosylation or lectin expression. To shed light on the in vivo situation, modulation of GAL1 binding at the surface of OP9 stromal cells in presence or in absence of l5-UR has been investigated by ow cytometry. No signicant variations have been observed (data not shown). It has been shown that GAL1 is involved in different processes through the interaction with several glycans expressed by multiple proteins7. As a consequence, a large amount of GAL1 is found associated to the stromal cell membrane even without the formation of a synapse with a pre-B cell18. We have shown in the current work that lots of the glycans do not undergo GAL1 afnity changes (Fig. 1c). We therefore believe that afnity changes with GAL1 would only be induced for glycans involved in pre-BCR clustering, but not for the glycans expressed by proteins unrelated to that process. This would mean that it would be possible to target specically one among several GAL1 cellular functions through a GAL1/unglycosylated protein interaction.
The use of lectin microarrays allowed us to investigate the glycome of Nalm6 pre-BII and OP9 stromal cells. Lectins have been used for decades to elucidate glycan structure and our latest mapping of their specicities with the glycan arrays of the CFG (see online data sets on CFG website and ref. 39) has given us an ability to clearly identify structures from our data sets especially when using multiple lectins in combination. The glycomic exploration of the pre-BII cells and stromal cells secreting GAL1 highlighted the presence of LacNAc epitopes at the pre-BII and stromal cell surfaces (Fig. 2) as well as a clear biantennary N-glycans and sulfated/a3 sialylated glycan signatures on pre-BII cells (Fig. 3). The presence of GAL1 ligands on both cell types supports the crucial role of GAL1 in pre-BII/stromal cell
recognition within the pre-BII cell niche. Indeed, it has been shown that pre-BII cells are not able to contact stromal cells that are not secreting GAL1 (ref. 21). The signicant LacNAc content of pre-BII cells is therefore an important determinant for cell recognition and cell niche specicity. Our glycome analysis combined to the structural and afnity modications observed on GAL1 when bound to l5-UR indicates that the GAL1/glycan lattice at the pre-B synapse is modied to the disadvantage of glycans present on both cells (polyLacNAc) but in the advantage of epitopes found preferentially on pre-BII cells (sulfated/a3 sialylated glycans). Currently, the model of synapse formation18,19 starts with the binding of stromal cell-derived GAL1 to pre-B cell glycosylated integrins and directly to the pre-BCR. Then, active integrin relocalization in the presence of GAL1 drives the pre-BCRs, through GAL1/pre-BCR interaction, into the pre-B/stromal cell synapse, leading to the initiation of pre-BCR signalling19. Our results complete this model (Fig. 8). Once exposed at the surface of the stromal cells, GAL1 is associated with stromal glycosylated receptors containing LacNAc epitopes (Fig. 8a). When the pre-BII cell contacts the stromal cell through the interaction between pre-BII cell integrins and their ligands on stromal cells (bronectin and ADAM-15, as previously identied19), GAL1 is able to interact with the pre-BCR (Fig. 8b). We have shown that this interaction weakens the strength of GAL1 binding to LacNAc epitopes, that is, to glycan motifs present on both cells. GAL1 bound to pre-BCR might then be able to interact with other glycan motifs (Fig. 8c) such as a3
SiaLacNAc (group (ii), Fig. 1c) found preferentially on pre-BII cells (Fig. 3). GAL1 acts as the molecular link between pre-BCRs and relocalizing integrins leading the pre-BCRs into the synapse where they are then activated (Fig. 8d). The reduced afnity of GAL1 for stromal cell ligands should thus help the pre-BCRs internalization by endocytosis which takes place after pre-BCR activation. Moreover, this dissociation should participate signicantly to the release of the pre-B cells from the niche, thus allowing the cells to migrate toward a new niche corresponding to another differentiation stage45. This spatial and temporal reorganization of the lattice would have direct consequences on synapse formation and dissolution. These interaction models are appealing as they help to explain how GAL1 can modify its lattice equilibria to form cell/cell contacts within a niche and subsequently modulate these contacts to
NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194
allow cell departure from the niche. These ndings may be extrapolated to other haematopoietic cell niches where there is increasing evidence that galectinglycan interactions control communication between haematopoietic and non-haematopoietic cells46.
More generally, GAL/glycan lattices include many pharmaceutically relevant targets that cover biologically important processes, such as proliferation, migration or apoptosis7,47. In this regard, galectin inhibitors that block the CRD have been developed for cancer treatment4850. Although promising, several of these inhibitors lack selectivity for individual members of the galectin family and often display weak ligand afnities. In this study, we provided the structural basis of a GAL1/glycan inhibition through the GAL1/l5-UR interaction. Our results provide the structural proof that it is possible to selectively inhibit GAL1/glycan interactions at distance of the CBS. Consequently, our results can be exploited for destabilization of GAL1/glycan interactions involved in cancers and will affect the development and design of new GAL1 inhibitors through GAL1/protein interactions.
Methods
Protein preparation. Plasmid encoding the human l5-UR domain was used26 to produce an amino-terminal His6 tag domain fused to a lipoyl sequence (17), followed by a tobacco etch virus cleavage site. For the purication of the l5-UR, the cells were disrupted using a French press, and the resulting supernatant was claried by centrifugation at 125,000g. The claried supernatant was applied to a 5- ml HisTrap HP column (GE Healthcare, Piscataway, NJ) in accordance with the manufacturers instructions. After elution, the lipoyl domain was removed from the l5-UR by tobacco etch virus protease digestion. The digestion mixture was applied to a HisTrap HP column. The ow-through containing the cleaved l5-UR was concentrated in an Amicon (Millipore) concentrator, and the samples were applied to a Superdex 75 (10/300GL) gel ltration column (GE Healthcare) as a nal purication step. For ITC experiments, the gene encoding human GAL1 was cloned into pET28a plasmid to produce a protein with a His6 amino-terminal tag.
After transformation of BL21(DE3) competent cells with the latter plasmid, bacteria were grown at 37 C until OD600nm 0.6 then 1 mM isopropyl-b-
D-
thiogalactoside was added to the culture to start overexpression of the protein. After 4 h incubation at 37 C, cells are harvested by centrifugation (3,000g, 15 min). After cell lysis, the His6-tagged GAL1 is puried from the supernatant by afnity chromatography using HiTrap 5 ml prepacked column plugged to an AKTAPrime purifying system. Protein is eluted using a linear gradient of imidazole and then loaded onto a gel ltration column for further purication. For NMR experiments,
15N-labelled GAL1 has been produced by growing the transformed cells inM9 minimal medium supplemented with 1 g l 1 15NH4Cl (ref. 26). Protein purity is checked by Coomassie blue staining of a SDSpolyacrylamide gel electrophoresis.
Peptide. The l5-UR22-45 peptide used in the ITC and NMR experiments was chemically synthesized and purchased (Schafer-N, Copenhagen, Denmark).
Carbohydrates. The chemically synthesized LNnT was offered by Core D of the Consortium for Functional Glycomics (CFG). a3 SiaLacNAc was purchased from ELICITYL company.
Glycan array screening. Puried GAL1 was uorescently labelled with Alexa Fluor 488 (Invitrogen) according to the manufacturers protocol and used (at a nal concentration of 5 mg ml 1 in the absence and in the presence of two molar excess of l5-UR) to probe versions 5.1 of the mammalian glycan array offered by Core H of the Consortium for Functional Glycomics (CFG). Each experiment has been performed on two biological replicates. The same experiments have been also performed at 25 mg ml 1 GAL1 concentration. For uorescence intensity comparison for each glycan between free and l5-UR-bound GAL1, relative uorescence intensities have been normalized according to the formula: RFUnorm (RFU/RFUmax)*100, where RFU is the relative uorescence intensity
measured and RFUmax is the maximal relative uorescence intensity measured on the array.
Isothermal titration calorimetry. ITC was used to evaluate the thermodynamics parameters of the binding between GAL1 protein domain and the selected carbohydrates. Puried GAL1 was extensively dialysed in the ITC buffer containing 20 mM phosphate buffer pH 7 or pH 5.2 when the inuence on GAL1 carbohydrate binding of either l5-UR or l5-UR22-45, respectively, was studied.
Carbohydrate powders were dissolved directly in the last protein dialysate before
experiments. Protein concentration was calculated by measuring the absorbance at 280 nm using a nanodrop ND1000 (Thermoscientic) and titrations were carried out on a MicroCal ITC200 microcalorimeter (GE Healthcare). Each experiment was designed using a titrant concentration (carbohydrate molecule in the syringe) set 10 to 15 times the analyte concentration (protein in the cell) and generally using 17 injections of 2.3 ml at 25 C (see Supplementary Table 1 for details). A rst small injection (generally 0.2 ml) was included in the titration protocol to remove air bubble trapped in the syringe prior titration. l5-UR or l5-UR22-45 peptide was added to the same concentration in both cell and syringe samples for tripartite titration experiments. Integrated raw ITC data were tted to a one-site non-linear least squares t model using the MicroCal Origin plugin as implemented in Origin9.1 (Origin Lab) after the control experiments (titration of the ligand from the syringe into the buffer) were subtracted. Titration experiments performed on GAL1 helped identifying that the protein concentration was generally overestimated in the cell (generally by 20%) due to stability issues. When the associated molar ratio (N value) could not converge during the tting process, the N value was set manually and maintained xed accordingly. Finally, DG and TDS values were calculated from the tted DH and KA values using the equations DG RTlnKA
and DG DHTDS.
NMR spectroscopy. The NMR experiments were performed at 303 K on a Bruker Avance III 600 MHz spectrometer equipped with a TCI cryoprobe. The NMR samples contained proteins in 20 mM phosphate buffer pH 5.2.
NMR titrations. The NMR titrations were performed using 2D 1H,15N HSQC NMR spectra recorded on 15N-labelled GAL1 (200 mM) in the absence and in the presence of l5-UR22-45 peptide (three molar excess). The carbohydrate-binding activity of GAL1 has been determined by recording 2D 1H,15N HSQC spectra of
15N-labelled GAL1 free or bound to l5-UR22-45 after addition of increasing amount of carbohydrate (0.1, 0.2, 0.3, 0.4, 0.8 and 2 mM).
The CSPs for each resonance were calculated using the equation:Ddobs [DdHN2 (DdN2/25)]1/2, where DdHN and DdN are, respectively, the proton
and nitrogen chemical shifts variation of each residue51.
STD NMR experiments. 1H and 13C NMR resonances assignment of LNnT have been performed using 2D 1H, 13C HSQC, 2D 1H, 13C HSQC-TOCSY, 2D 1H,
1H-TOCSY and 2D 1H, 1H-COSY experiments.
The 1D STD (128 scans, 32 K data points) and the 2D STD TOCSY experiments (mixing time 60 ms with 512 increments of 128 scans each) were performed using a 100:1 LNnT/GAL1 and a 100:1:3 LNnT/GAL1/l5-UR22-45 molar ratio samples, with a 1 mM concentration of LNnT. The 1D and 2D STD spectra were recorded with on resonance irradiation at 7.0 p.p.m. and off resonance irradiation at40 p.p.m. and were performed with a saturation time of 2 s.
Cell lines. The OP9 and Nalm6 cell lines have been used in the present study since they are able to contact with each other and mediate pre-BCR relocalization26. The murine stromal cell line OP9 (ref. 52) was cultivated in MEMa, 20% fetal calf serum, 100 U ml 1 penicillin and 100 mg ml 1 streptomycin. The cells were mechanically detached from the dishes using cell scrapers to avoid the use of trypsine. In the OP9 lactose-treated cells, lactose was added to the culture at 0.2 M concentration during 1 h. The human pre-B cell line Nalm6 (ref. 53) was cultivated in RPMI, 10% fetal calf serum, 100 U ml 1 penicillin, 100 mg ml 1 streptomycin and 50 mM b-mercaptoethanol.
Lectin microarrays. All cell samples were prepared and Cy labelled as follows37: cells were harvested using a cell scraper and then pelleted (500g) and resuspended in PBS. Sonication has been performed and cellular micellae were isolated by means of ultracentrifugation (100,000g). We resuspended the pellet in Cy-labelling buffer (0.1 M NaCO3 in H2O, pH 9.3). At this point, we determined the protein concentration by using the DC protein assay (Bio-Rad). We then added at least 10 mg of Cy3- or Cy5- NHS (GE Life Sciences) to 1 mg of cell membrane (as determined by protein content) and incubated for 30 min at room temperature. The labelled cell membrane preps were then dialysed against PBS overnight at 4 C, aliquoted and snap frozen in liquid N2. Aliquots were stored at 80 C. A
reference sample was made by combining equal amounts of OP9 bioreplicated samples into one and labelled. All lectins were purchased from either EY Laboratories (San Mateo, CA) or Vector Laboratories (Burlingame, CA) except TJA-I, TJA-II (NorthStar Bioproducts), cyanovirin (CVN) and scytovirin (SVN; gifts from Dr B. OKeefe, NCI Frederick). Arrays were printed on Nexterion H slides (SCHOTT North America Inc., Elmsford, NY) using a non-contact printer with piezoelectric dispensing (Nanoplotter 2.1, GeSIM, Germany) at 12 C and 43% humidity with three spots per lectin per array. Hybridization was performed as previously described54. In brief, equal amounts of Cy5-labelled sample was hybridized against Cy3-labelled reference and incubated for 2 h at 25 C (4 mg total protein brought to a volume of 100 ml with PBS with Tween-20 per array). Lectin activity was monitored using glycoprotein standards to test each array print. Slides were scanned in a GenePix 4300A scanner under normal acquisition mode using GenePix Pro 7.2. The background-subtracted median uorescence for the three
10 NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194 ARTICLE
spots per lectin were averaged and log2 transformed. Signal averages less than 1,000 for both channels were excluded. Lectins with a signal-to-noise ratio o5 for more than 30% of the total data were also excluded. This left 67 of the 107 lectins printed on the array. Each channel was then median normalized per array and the log2 ratio of sample over reference was calculated.
References
1. Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A. & Dwek, R. A. Glycosylation and the immune system. Science 291, 23702376 (2001).
2. Bertozzi, C. R. & Kiessling, L. L. Chemical glycobiology. Science 291, 23572364 (2001).
3. Hughes, R. C. Galectins as modulators of cell adhesion. Biochimie 83, 667676 (2001).
4. Dam, T. K., Roy, R., Das, S. K., Oscarson, S. & Brewer, C. F. Binding of multivalent carbohydrates to concanavalin A and Dioclea grandiora lectin. Thermodynamic analysis of the multivalency effect. J. Biol. Chem. 275, 1422314230 (2000).
5. Gupta, D., Kaltner, H., Dong, X., Gabius, H. J. & Brewer, C. F. Comparative cross-linking activities of lactose-specic plant and animal lectins and a natural lactose-binding immunoglobulin G fraction from human serum with asialofetuin. Glycobiology 6, 843849 (1996).
6. Collins, B. E. & Paulson, J. C. Cell surface biology mediated by low afnity multivalent protein-glycan interactions. Curr. Opin. Chem. Biol. 8, 617625 (2004).
7. Brewer, C. F., Miceli, M. C. & Baum, L. G. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr. Opin. Struct. Biol. 12, 616623 (2002).
8. Hirabayashi, J. et al. Oligosaccharide specicity of galectins: a searchby frontal afnity chromatography. Biochim. Biophys. Acta 1572, 232254 (2002).
9. Patnaik, S. K. et al. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells. Glycobiology 16, 305317 (2006).10. Barondes, S. H., Cooper, D. N., Gitt, M. A. & Lefer, H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 269, 2080720810 (1994).
11. Scott, K. & Weinberg, C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj. J. 19, 467477 (2004).
12. Park, J. W., Voss, P. G., Grabski, S., Wang, J. L. & Patterson, R. J. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res. 29, 35953602 (2001).
13. Perillo, N. L., Pace, K. E., Seilhamer, J. J. & Baum, L. G. Apoptosis of T cells mediated by galectin-1. Nature 378, 736739 (1995).
14. Liu, F. T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 2941 (2005).
15. Camby, I., Le Mercier, M., Lefranc, F. & Kiss, R. Galectin-1: a small protein with major functions. Glycobiology 16, 137R157R (2006).
16. Lefer, H., Carlsson, S., Hedlund, M., Qian, Y. & Poirier, F. Introduction to galectins. Glycoconj. J. 19, 433440 (2004).
17. Lpez-Lucendo, M. F. et al. Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding.J. Mol. Biol. 343, 957970 (2004).18. Gauthier, L., Rossi, B., Roux, F., Termine, E. & Schiff, C. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc. Natl Acad. Sci. USA 99, 1301413019 (2002).
19. Rossi, B., Espeli, M., Schiff, C. & Gauthier, L. Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation.J. Immunol. 177, 796803 (2006).20. Espeli, M., Mancini, S., Breton, C., Poirier, F. & Schiff, C. Impaired B-cell development at the pre-BII-cell stage in galectin-1-decient mice due to inefcient pre-BII/stromal cell interactions. Blood 113, 58785886 (2009).
21. Mourcin, F. et al. Galectin-1-expressing stromal cells constitute a specic niche for pre-BII cell development in mouse bone marrow. Blood 117, 65526561 (2011).
22. Goodnow, C. C., Sprent, J., Fazekas de St Groth, B. & Vinuesa, C. G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590597 (2005).
23. Kitamura, D., Roes, J., Khn, R. & Rajewsky, K. A B cell-decient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350, 423426 (1991).
24. Ohnishi, K. & Melchers, F. The nonimmunoglobulin portion of lambda5 mediates cell-autonomous pre-B cell receptor signaling. Nat. Immunol. 4, 849856 (2003).
25. Knoll, M. et al. The non-Ig parts of the VpreB and l5 proteins of the surrogate light chain play opposite roles in the surface representation of the precursor B cell receptor. J. Immunol. 188, 60106017 (2012).
26. Elantak, L. et al. Structural basis for galectin-1-dependent pre-B cell receptor (Pre-BCR) activation. J. Biol. Chem. 287, 4470344713 (2012).
27. Salomonsson, E., Thijssen, V. L., Grifoen, A. W., Nilsson, U. J. & Lefer, H. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding afnity for glycoproteins. J. Biol. Chem. 286, 1380113804 (2011).
28. Grifoen, A. W. et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 354, 233242 (2001).
29. van der Schaft, D. W. et al. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 16, 19911993 (2002).
30. Stowell, S. R. et al. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. J. Biol. Chem. 283, 1010910123 (2008).
31. Stowell, S. R. et al. Human galectin-1 recognition of poly-N-acetyllactosamine and chimeric polysaccharides. Glycobiology 14, 157167 (2004).32. Ahmad, N., Gabius, H. J., Sabesan, S., Oscarson, S. & Brewer, C. F. Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3. Glycobiology 14, 817825 (2004).
33. Gupta, G., Surolia, A. & Sampathkumar, S. G. Lectin microarrays for glycomic analysis. OMICS 14, 419436 (2010).
34. Krishnamoorthy, L. & Mahal, L. K. Glycomic analysis: an array of technologies. ACS Chem. Biol. 4, 715732 (2009).
35. Krishnamoorthy, L., Bess, J. J., Preston, A., Nagashima, K. & Mahal, L. HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat. Chem. Biol. 5, 244250 (2009).
36. Hsu, K. L., Pilobello, K. T. & Mahal, L. K. Analyzing the dynamic bacterial glycome with a lectin microarray approach. Nat. Chem. Biol. 2, 153157 (2006).
37. Pilobello, K. T., Slawek, D. E. & Mahal, L. K. A ratiometric lectin microarray approach to analysis of the dynamic mammalian glycome. Proc. Natl Acad. Sci. USA 104, 1153411539 (2007).
38. Kuno, A., Matsuda, A., Ikehara, Y., Narimatsu, H. & Hirabayashi, J. Differential glycan proling by lectin microarray targeting tissue specimens. Methods Enzymol. 478, 165179 (2010).
39. Agrawal, P., Smith, D., Eng, W., Cummings, R. & Mahal, L. Large scale glycan array analysis of commercial lectins and antibodies: 86 lectins and 15 antibodies. Glycobiology 22, 16461646 (2012).
40. Nesmelova, I. et al. Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity. J. Mol. Biol. 397, 12091230 (2010).
41. Mayer, M. & Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38, 17841788 (1999).
42. Rabinovich, G. A., Toscano, M. A., Jackson, S. S. & Vasta, G. R. Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 17, 513520 (2007).
43. Dings, R. P. et al. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J. Med. Chem. 55, 51215129 (2012).
44. Dings, R. P. et al. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J. Natl Cancer Inst. 98, 932936 (2006).
45. Nagasawa, T. Microenvironmental niches in the bone marrow required for B-cell development. Nat. Rev. Immunol. 6, 107116 (2006).
46. Rabinovich, G. A. & Vidal, M. Galectins and microenvironmental niches during hematopoiesis. Curr. Opin. Hematol. 18, 443451 (2011).
47. Paulson, J. C., Blixt, O. & Collins, B. E. Sweet spots in functional glycomics. Nat. Chem. Biol. 2, 238248 (2006).
48. Ingrassia, L. et al. Anti-galectin compounds as potential anti-cancer drugs. Curr. Med. Chem. 13, 35133527 (2006).
49. Rabinovich, G. A. et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 16, 210220 (2006).
50. Ito, K. & Ralph, S. J. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4( ) and CD8 ( ) T cells and reduced cancer cell adherence.
Clin. Exp. Metastasis 29, 561572 (2012).51. Grzesiek, S. et al. The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nat. Struct. Biol. 3, 340345 (1996).
52. Kodama, H., Nose, M., Niida, S. & Nishikawa, S. Involvement of the c-kit receptor in the adhesion of hematopoietic stem cells to stromal cells. Exp. Hematol. 22, 979984 (1994).
53. Hurwitz, R. et al. Characterization of a leukemic cell line of the pre-B phenotype. Int. J. Cancer 23, 174180 (1979).
54. Pilobello, K. T., Agrawal, P., Rouse, R. & Mahal, L. K. Advances in lectin microarray technology: optimized protocols for piezoelectric print conditions. Curr. Protoc. Chem. Biol. 5, 123 (2013).
NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7194
Acknowledgements
We would like to thank the Consortium for Functional Glycomics for providing the Glycan Arrays and the Core H at Emory University for the screenings. The raw glycan array data are posted on the CFG website (http://www.functionalglycomics.org
Web End =www.functionalglycomics.org). We thank Annie Boned for her help in cell cultures. This work was supported by the Centre National de la Recherche Scientique (CNRS)PEPS 2010 Grant to L.E. L.K.M. acknowledges support from the Margaret and Herman Faculty Award Fund.
Author contributions
L.E. designed the project. J.B. expressed and labelled accordingly all the proteins used in this study. J.B. and L.E. analysed the NMR experiments and glycan array data. O.B. set-up and recorded the NMR experiments. J.B. and S.B. performed and analysed the ITC experiments. B.T.K. and L.K.M. performed and analysed the lectin microarray experiments. J.B., S.J.M. and C.S. prepared and provided cells for the lectin microarray
experiments. F.G. and C.S.-K. participated in the interpretation of the data. L.E. and F.G. wrote the paper; all authors discussed the results and approved the manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications
Web End =http://www.nature.com/ http://www.nature.com/naturecommunications
Web End =naturecommunications .
Competing nancial interests: The authors declare no competing nancial interests.
Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions
Web End =http://npg.nature.com/ http://npg.nature.com/reprintsandpermissions
Web End =reprintsandpermissions/
How to cite this article: Bonzi, J. et al. Pre-B cell receptor binding to galectin-1 modies galectin-1/carbohydrate afnity to modulate specic galectin-1/glycan lattice interactions. Nat. Commun. 6:6194 doi: 10.1038/ncomms7194 (2015).
12 NATURE COMMUNICATIONS | 6:6194 | DOI: 10.1038/ncomms7194 | http://www.nature.com/naturecommunications
Web End =www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright Nature Publishing Group Feb 2015
Abstract
Galectins are glycan-binding proteins involved in various biological processes including cell/cell interactions. During B-cell development, bone marrow stromal cells secreting galectin-1 (GAL1) constitute a specific niche for pre-BII cells. Besides binding glycans, GAL1 is also a pre-B cell receptor (pre-BCR) ligand that induces receptor clustering, the first checkpoint of B-cell differentiation. The GAL1/pre-BCR interaction is the first example of a GAL1/unglycosylated protein interaction in the extracellular compartment. Here we show that GAL1/pre-BCR interaction modifies GAL1/glycan affinity and particularly inhibits binding to LacNAc containing epitopes. GAL1/pre-BCR interaction induces local conformational changes in the GAL1 carbohydrate-binding site generating a reduction in GAL1/glycan affinity. This fine tuning of GAL1/glycan interactions may be a strategic mechanism for allowing pre-BCR clustering and pre-BII cells departure from their niche. Altogether, our data suggest a novel mechanism for a cell to modify the equilibrium of the GAL1/glycan lattice involving GAL1/unglycosylated protein interactions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer